VoyagerTherapeutics Inc. (NASDAQ: VYGR) was up 4% on Friday after the company announced the presentation of preclinical data showing that intravenous dosing of the novel AAV vectorized antibody by the TRACER screening tech, incorporating anti-HER2 antibody payload, can prevent the growth of tumor in HER2+ brain metastases models. Key findings of the study will be presented by Dan R. Laks, voyager Scientist II.
Trading Data
On Friday, VYGR stock went up 4.11% to $3.29 with more than 1.09 million shares, compared to its average volume of 5.55 million shares. The stock has moved within a range of $3.1020 – 3.3700 after opening trade at $3.19.
Voyager Therapeutics Announces Positive Preclinical Data from New Vectorized anti-HER2 Antibody Program at the 26th Society for Neuro-Oncology Annual Meeting
The company’s interim chief scientific officer Glenn Pierce said that the findings indicate that transfer of the AAV gene of HER2 antibodies to the CNS is promising in bran metastates treatment in HER2+ breast cancer patients. Glenn said that although approved Anti-HER2 treatments show efficacy in peripheral disease, they have limited ability to reach the central nervous system in inadequate proportions for brain metastases treatment.
However, the use of TRACE AAV capsid in delivering the company’s vectorized payload and using brain cells producing antibodies has shown durable effects against various CNS tumours in animal models. VYGR is worth watching in the coming days.
Key Quote
“Today’s findings demonstrate that AAV gene transfer of HER2-directed antibodies to the central nervous system shows promise to treat brain metastases in patients with HER2+ breast cancer,” said Glenn Pierce, M.D., Ph.D., interim chief scientific officer of Voyager. “While approved anti-HER2 therapies are effective for peripheral disease, they have limited ability to reach the CNS in sufficient concentrations to treat brain metastases. By using a proprietary, TRACER AAV capsid to deliver Voyager’s vectorized payload, and by utilizing brain cells to produce therapeutic antibodies, we have demonstrated a durable effect against CNS tumors in several mouse models. We look forward to continued optimization of this innovative gene therapy approach as we progress toward clinical development.”
Technical Data
VYGR stock is trading below the 20-Day and 50-Day Moving averages of $3.55 and $3.56 respectively. Moreover, the stock is trading below the 200-Day moving average of $4.25. The stock is down 28% in the past month.
